Abstract
During the last quarter of 2000, the U.S. Public Health Service learned of a shortage of tetanus and diphtheria toxoids (Td) and tetanus toxoid (TT) resulting from decreased production of these vaccines by the two U.S. manufacturers. Previously published recommendations outlined priorities for use of the limited supply of Td and TT. The shortage was expected to be resolved by early 2001; however, on January 10, 2001, Wyeth Lederle (Pearl River, New York) announced it had stopped production of tetanus toxoid-containing products. Although a small amount of Td is produced by the University of Massachusetts for local distribution, Aventis Pasteur (Swiftwater, Pennsylvania) is now the sole nationwide distributor of Td and TT. Aventis Pasteur is shipping limited quantities of vaccine to assure a wide distribution of available doses.
Highlights
Introduction to Public HealthSurveillance CourseMMWR. 2001;50:149CDC AND EMORY UNIVERSITY’S ROLlins School of Public Health will cosponsor a course, “Introduction to Public Health Surveillance” during June18-22, 2001, in Atlanta, Georgia
U.S Public Health Service learned of a shortage of tetanus and diphtheria toxoids (Td) and tetanus toxoid (TT) resulting from decreased production of these vaccines by the two U.S manufacturers
diphtheria toxoids and acellular pertussis vaccine (DTaP) vaccine is recommended as a five-dose series: three doses given to infants at ages [2, 4], and 6 months, followed by two booster doses at age [15,16,17,18] months and at age [4,5,6] years.[2]
Summary
U.S Public Health Service learned of a shortage of tetanus and diphtheria toxoids (Td) and tetanus toxoid (TT) resulting from decreased production of these vaccines by the two U.S manufacturers. Aventis Pasteur is shipping limited quantities of vaccine to assure a wide distribution of available doses. In accordance with previous recommendations, priority will be given to clinics and hospitals that treat acute wounds; continuing to prioritize Td and TT use will be necessary until supplies are restored.[1] Clinics and hospitals in need of vaccine for wound care should call Aventis Pasteur, telephone (800) 822-2463. Drug Administration approved a newly formulated version of Tripediat in onedose vials without preservative and with only a trace amount of thimerosal Approval of this vaccine should improve the supply of DTaP. Children aged [4,5,6] years should be vaccinated in accordance with existing ACIP recommendations to assure immunity to pertussis, diphtheria, and tetanus during the elementary school years. CDC is evaluating the situation, and more guidance will be provided should substantial supply problems occur
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
